Results 111 to 120 of about 34,187 (225)

Radiation risk for employees involved in the validation of methods to control radiochemical impurity in technetium-99m radiopharmaceuticals [PDF]

А. О. Малышева, E. A. Lyamtseva, Н. А. Таратоненкова, A.S. Lunev   +3 more
openalex   +1 more source

Design of Stimuli‐Responsive Cobalt Tetraphenylporphyrinate‐Chitosan Microspheres for Advanced Biosensors

European Journal of Inorganic Chemistry, Volume 29, Issue 3, January 21, 2026.
We report on new cobalt tetraphenylporphyrinate‐chitosan‐based microspheres developed for biosensing and anticancer therapy applications. We analyzed their second‐harmonic generation (SHG) behavior using a high‐resolution SHG microscope. In addition to the typical porphyrinate fluorescence, the microspheres exhibit a high‐intensity SHG response and ...
Domenica Marabello, Paola Benzi, Carlo Canepa, Leonardo Mortati, Giorgio Volpi, Itzel M. Garnica‐Palafox, Francisco M. Sánchez‐Arévalo, Nadia A. Vázquez‐Torres, Alma Cioci   +8 more
wiley   +1 more source

3D small-scale dosimetry and tumor control of 225Ac radiopharmaceuticals for prostate cancer [PDF]

Robin Peter, Anil P. Bidkar, Kondapa Naidu Bobba, Luann Zerefa, Chandrashekhar Dasari, Niranjan Meher, Anju Wadhwa, Adam Oskowitz, Bin Liu, Brian W. Miller, K. Vetter, Robert R. Flavell, Youngho Seo   +12 more
openalex   +1 more source

Epigenomics‐guided precision oncology: Chromatin variants in prostate tumor evolution

International Journal of Cancer, Volume 158, Issue 2, Page 314-332, 15 January 2026.
Abstract Prostate cancer is a common malignancy that in 5%–30% leads to treatment‐resistant and highly aggressive disease. Metastasis‐potential and treatment‐resistance is thought to rely on increased plasticity of the cancer cells—a mechanism whereby cancer cells alter their identity to adapt to changing environments or therapeutic pressures to create
Kira Furlano, Tina Keshavarzian, Nadine Biernath, Annika Fendler, Maria de Santis, Joachim Weischenfeldt, Mathieu Lupien   +6 more
wiley   +1 more source

Protein-based Radiopharmaceuticals that target fibroblast activation protein alpha: a review of current progress

EJNMMI Radiopharmacy and Chemistry
Background Fibroblast activation protein alpha (FAP) is a serine protease that is expressed at basal levels in benign tissues but is overexpressed in a variety of pathologies, including cancer.
Abdelrahman Homedan, Darpan N. Pandya, Nicholas J. Schnicker, Thaddeus J. Wadas   +3 more
doaj   +1 more source

Simplification of Methods for PET Radiopharmaceutical Syntheses

, 2011
M. Ritzert
openalex   +2 more sources

A Consensus Time for Performing Quality Control of 225Ac-Labeled Radiopharmaceuticals

, 2021
James M. Kelly, Alejandro Amor‐Coarasa, Elizabeth Sweeney, Justin J. Wilson, Patrick Causey, John W. Babich   +5 more
openalex   +1 more source

Coded aperture and Compton imaging for the development of ²²⁵Ac‐based radiopharmaceuticals [PDF]

, 2023
Emily Frame, Kondapa Bobba, Donald Gunter, Lucian Mihailescu, Anil P. Bidkar, Robert R. Flavell, K. Vetter   +6 more
openalex   +1 more source

In vivo stability of ²¹¹At-radiopharmaceuticals: on the impact of halogen bond formation

, 2023
Thibault Yssartier, Lu Liu, Sylvain Pardoue, Jean‐Yves Le Questel, François Guérard, Gilles Montavon, Nicolas Galland   +6 more
openalex   +2 more sources

Availability of Radiopharmaceuticals and Imaging Equipment in English-Speaking African Countries. [PDF]

J Nucl Med Technol
Mosima LS, Manicum AE, Summers B.
europepmc   +1 more source